Recently, ALung hosted a webinar on the use of Hemolung RAS to treat COVID-19 patients.  Four physicians review COVID-19 patient cases and present their findings.


“The Role of ECCO2R in COVID-19 with Real World Physician Experience”.

Click here to watch the video of the webinar.


COPD affects 30 million Americans and is the third leading cause of death in the United States behind cancer and heart disease.

Acute exacerbations, defined as a sudden worsening of COPD symptoms, are a major cause of morbidity and mortality in COPD patients. For patients with severe exacerbations, high levels of carbon dioxide can result in respiratory failure and the need for intubation and mechanical ventilation as life saving measures. Unfortunately, mechanical ventilation is associated with many side effects, and in-hospital mortality remains as high as 30%.

ECCO₂R therapy with the Hemolung RAS allows carbon dioxide to be removed from the blood independently of the lungs with the aim of facilitating the avoidance or reduction of intubation and invasive mechanical ventilation.

CAUTION: The Hemolung RAS is an Investigational Device and limited by United States law to investigational use.

2014 – ALung treats first US Patient in emergency use.

ALung’s Hemolung RAS has CE Mark and is currently undergoing an FDA PMA trial for clearance in the US (VENT-AVOID Trial).

ALung is currently conducting a pivotal IDE trial of the Hemolung Respiratory Assist System for the treatment of adults with severe acute exacerbations of chronic obstructive pulmonary disease (COPD). The VENT-AVOID Trial is the first pivotal trial of extracorporeal carbon dioxide removal (ECCO2R) for treating patients with COPD exacerbations.

ECCO2R removes excess carbon dioxide directly from a patient's bloodstream.
The first pivotal clinical trial of ECCO2R in patients with COPD.
Resources for US-based VENT-AVOID Trial sites.